Genetic Technologies : Notice of 2016 Annual General Meeting and Sample Proxy

ASX ANNOUNCEMENT‌ 24 October 2016 Notice of 2016 Annual General Meeting and Sample Proxy

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company") is pleased to release its Notice of the 2016 Annual General Meeting of shareholders (the "Notice") together with a Sample Proxy.

The Notice and a personalised proxy is being mailed to all shareholders and the Company's 2016 Annual Report is available for download from its website: www.gtglabs.com

As detailed in the Notice, the 2016 Annual General Meeting will be held at 10.30 am on Wednesday, 23 November 2016, at the following address:

"Treetops" Melbourne Museum 11 Nicholson Street

Carlton, Victoria 3053 Australia

About Genetic Technologies Limited

Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The Company's lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus® improves upon the predictive power of the first generation BREVAGen™ test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus® expands the application of BREVAGen™ from Caucasian women to include African- Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.

The Company has successfully launched the first generation BREVAGen™ test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGenplus®, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGenplus® to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons).

For more information, please visit www.brevagenplus.comandwww.phenogensciences.com.

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

FOR FURTHER INFORMATION PLEASE CONTACT

Mr. Eutillio Buccilli Candice Knoll (USA) Executive Director & Chief Executive Officer Blueprint Life Science Group Genetic Technologies Limited [phone], Ext. 4

+ 61 3 8412 7050

Genetic Technologies

Personalising health

2016 NOTICE OF ANNUAL GENERAL MEETING

Notice is given that the Annual General Meeting

of the shareholders of Genetic Technologies Limited

(ACN 009 212 328) will be held at:

10.30am onWednesday, 23 November 2016 at "Treetops", Melbourne Museum

11 Nicholson Street

Carlton, Victoria 3053 Australia

This page has been left blank intentionally.

02